301 related articles for article (PubMed ID: 34228539)
1. Assessment of Mortality-Related Risk Factors and Effective Antimicrobial Regimens for Treatment of Bloodstream Infections Caused by Carbapenem-Resistant
Chen L; Han X; Li Y; Li M
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0069821. PubMed ID: 34228539
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant
Chen Y; Huang HB; Peng JM; Weng L; Du B
Microbiol Spectr; 2022 Apr; 10(2):e0260321. PubMed ID: 35377233
[TBL] [Abstract][Full Text] [Related]
3. Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant
Zhen S; Zhao Y; Chen Z; Zhang T; Wang J; Jiang E; Zhang F; Mi Y; Zhu X; Han M; Xiao Z; Wang J; Feng S
Front Cell Infect Microbiol; 2023; 13():1156651. PubMed ID: 37415825
[TBL] [Abstract][Full Text] [Related]
4. Bloodstream infections due to Carbapenem-Resistant Enterobacteriaceae in hematological patients: assessment of risk factors for mortality and treatment options.
Zhang L; Zhen S; Shen Y; Zhang T; Wang J; Li J; Lin Q; Xiao Z; Zheng Y; Jiang E; Han M; Wang J; Feng S
Ann Clin Microbiol Antimicrob; 2023 May; 22(1):41. PubMed ID: 37202758
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and mortality of ceftazidime/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study.
Zhuang HH; Chen Y; Hu Q; Long WM; Wu XL; Wang Q; Xu TT; Qu Q; Liu YP; Xiao YW; Qu J
J Infect Public Health; 2023 Jun; 16(6):938-947. PubMed ID: 37087853
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae.
Pérez-Nadales E; Fernández-Ruiz M; Natera AM; Gutiérrez-Gutiérrez B; Mularoni A; Russelli G; Pierrotti LC; Pinheiro Freire M; Falcone M; Tiseo G; Tumbarello M; Raffaelli F; Abdala E; Bodro M; Gervasi E; Fariñas MC; Seminari EM; Castón JJ; Marín-Sanz JA; Gálvez-Soto V; Rana MM; Loeches B; Martín-Dávila P; Pascual Á; Rodríguez-Baño J; Aguado JM; Martínez-Martínez L; Torre-Cisneros J;
Am J Transplant; 2023 Jul; 23(7):1022-1034. PubMed ID: 37028515
[TBL] [Abstract][Full Text] [Related]
7. Rectal culture could predict carbapenem-resistant organism bloodstream infection and reduce the mortality in haematological patients: A retrospective cohort study.
Gao S; Yan R; Zhang S; Li L; Zhang R; Fan J; Qin J; Peng Y; Wan D; Cao W; Bian Z
J Glob Antimicrob Resist; 2024 Mar; 36():96-104. PubMed ID: 38128727
[TBL] [Abstract][Full Text] [Related]
8. Double-, single- and none-carbapenem-containing regimens for the treatment of carbapenem-resistant Enterobacterales (CRE) bloodstream infections: a retrospective cohort.
Rigatto MH; Ramos F; Barros A; Pedroso S; Guasso I; Gonçalves L; Bergo P; Zavascki AP
J Antimicrob Chemother; 2022 Oct; 77(11):3118-3125. PubMed ID: 36048569
[TBL] [Abstract][Full Text] [Related]
9. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital.
Li C; Li Y; Zhao Z; Liu Q; Li B
J Infect Public Health; 2019; 12(1):26-31. PubMed ID: 30145151
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes and Risk Factors for Carbapenem-resistant Enterobacterales Bloodstream Infection in Solid Organ Transplant Recipients.
Anesi JA; Lautenbach E; Thom KA; Tamma PD; Blumberg EA; Alby K; Bilker WB; Werzen A; Ammazzalorso A; Tolomeo P; Omorogbe J; Pineles L; Han JH
Transplantation; 2023 Jan; 107(1):254-263. PubMed ID: 35856636
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.
Falcone M; Daikos GL; Tiseo G; Bassoulis D; Giordano C; Galfo V; Leonildi A; Tagliaferri E; Barnini S; Sani S; Farcomeni A; Ghiadoni L; Menichetti F
Clin Infect Dis; 2021 Jun; 72(11):1871-1878. PubMed ID: 32427286
[TBL] [Abstract][Full Text] [Related]
12. Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically Ventilated Patients.
Tsolaki V; Mantzarlis K; Mpakalis A; Malli E; Tsimpoukas F; Tsirogianni A; Papagiannitsis C; Zygoulis P; Papadonta ME; Petinaki E; Makris D; Zakynthinos E
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818820
[TBL] [Abstract][Full Text] [Related]
13. Carbapenem-resistant
Ruvinsky S; Voto C; Roel M; Deschutter V; Ferraro D; Aquino N; Reijtman V; Galvan ME; Motto E; García M; Sarkis C; Bologna R
Front Public Health; 2022; 10():983174. PubMed ID: 36091556
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant
Kong W; Yang X; Shu Y; Li S; Song B; Yang K
Front Public Health; 2023; 11():1118307. PubMed ID: 36926178
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.
Alraddadi BM; Saeedi M; Qutub M; Alshukairi A; Hassanien A; Wali G
BMC Infect Dis; 2019 Sep; 19(1):772. PubMed ID: 31484510
[TBL] [Abstract][Full Text] [Related]
16. Bloodstream Infections Caused by Carbapenem-Resistant
Zhou C; Jin L; Wang Q; Wang X; Chen F; Gao Y; Zhao C; Chen H; Cao B; Wang H
Infect Drug Resist; 2021; 14():731-742. PubMed ID: 33658810
[TBL] [Abstract][Full Text] [Related]
17. Mortality Attributable to Bloodstream Infections Caused by Different Carbapenem-Resistant Gram-Negative Bacilli: Results From a Nationwide Study in Italy (ALARICO Network).
Falcone M; Tiseo G; Carbonara S; Marino A; Di Caprio G; Carretta A; Mularoni A; Mariani MF; Maraolo AE; Scotto R; Dalfino L; Corbo L; Macera M; Medaglia AA; d'Errico ML; Gioè C; Sgroi C; Del Vecchio RF; Ceccarelli G; Albanese A; Buscemi C; Talamanca S; Raponi G; Foti G; De Stefano G; Franco A; Iacobello C; Corrao S; Morana U; Pieralli F; Gentile I; Santantonio T; Cascio A; Coppola N; Cacopardo B; Farcomeni A; Venditti M; Menichetti F;
Clin Infect Dis; 2023 Jun; 76(12):2059-2069. PubMed ID: 36801828
[TBL] [Abstract][Full Text] [Related]
18. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by
Guimarães T; Nouér SA; Martins RCR; Perdigão Neto LV; Martins WMBS; Narciso Barbosa AC; Ferreira ALP; Costa SF; Gales AC
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358592
[TBL] [Abstract][Full Text] [Related]
19. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.
Temkin E; Torre-Cisneros J; Beovic B; Benito N; Giannella M; Gilarranz R; Jeremiah C; Loeches B; Machuca I; Jiménez-Martín MJ; Martínez JA; Mora-Rillo M; Navas E; Osthoff M; Pozo JC; Ramos Ramos JC; Rodriguez M; Sánchez-García M; Viale P; Wolff M; Carmeli Y
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895014
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for Carbapenem-Resistant
Rebold N; Lagnf AM; Alosaimy S; Holger DJ; Witucki P; Mannino A; Dierker M; Lucas K; Kunz Coyne AJ; El Ghali A; Caniff KE; Veve MP; Rybak MJ
Microbiol Spectr; 2023 Feb; 11(1):e0264722. PubMed ID: 36622246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
